Treatment of drug-susceptible and drug-resistant tuberculosis

Recent advances have enabled the use of shorter TB treatment regimens. Key changes in the management of TB are: 1-month preventive treatment with rifapentine and isoniazid 4-month treatment for paucibacillary TB in children 4-month treatment for PTB in adults based on rifapentine and 6-month treatment for MDR/RR-TB with bedaquiline, pretomanid, linezolid and moxifloxacin (BPaLM). However, the history of TB drug resistance, and limited capacity worldwide for DST, are cause for caution.